Insider Selling: Definium Therapeutics (NASDAQ:DFTX) CEO Sells 31,550 Shares of Stock

Definium Therapeutics, Inc. (NASDAQ:DFTX) CEO Robert Barrow sold 31,550 shares of Definium Therapeutics stock in a transaction on Friday, September 25th. The stock was sold at an average price of $36.57, for a total value of $1,153,783.50. Following the completion of the transaction, the chief executive officer owned 2,213,090 shares in the company, valued at $80,932,701.30. The trade was a 1.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Robert Barrow also recently made the following trade(s):

• On Thursday, September 3rd, Robert Barrow sold 19,023 shares of Definium Therapeutics stock. The stock was sold at an average price of $37.94, for a total transaction of $721,732.62.

Definium Therapeutics Trading Down 0.5%

Shares of DFTX stock traded down $0.20 during trading hours on Tuesday, reaching $38.21. 1,967,182 shares of the stock traded hands, compared to its average volume of 2,245,960. The company has a quick ratio of 6.95, a current ratio of 6.95 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $5.13 billion, a PE ratio of -11.14 and a beta of 2.23. Definium Therapeutics, Inc. has a 1-year low of $10.46 and a 1-year high of $49.70. The business has a fifty day moving average price of $41.37 and a 200 day moving average price of $32.06.

Definium Therapeutics (NASDAQ:DFTX) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($1.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). On average, equities research analysts forecast that Definium Therapeutics, Inc. will post -3.02 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Avoro Capital Advisors LLC bought a new stake in shares of Definium Therapeutics in the fourth quarter valued at about $66,950,000. Wellington Management Group LLP acquired a new stake in Definium Therapeutics during the second quarter worth $138,755,000. Seven Fleet Capital Management LP acquired a new position in shares of Definium Therapeutics in the 2nd quarter valued at $6,992,000. Platinum Investment Management Ltd. bought a new position in shares of Definium Therapeutics during the 4th quarter worth about $937,000. Finally, TD Waterhouse Canada Inc. acquired a new stake in shares of Definium Therapeutics during the 2nd quarter valued at about $1,592,000. Institutional investors and hedge funds own 27.91% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. JonesTrading lifted their price target on Definium Therapeutics from $74.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, August 13th. HC Wainwright reaffirmed a “buy” rating and set a $70.00 price objective on shares of Definium Therapeutics in a research report on Monday, September 14th. Leerink Partners set a $52.00 target price on shares of Definium Therapeutics and gave the stock an “outperform” rating in a research report on Monday, June 22nd. Robert W. Baird upped their price target on shares of Definium Therapeutics from $75.00 to $79.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 15th. Finally, Canaccord Genuity Group set a $78.00 price objective on Definium Therapeutics and gave the company a “buy” rating in a research report on Tuesday, September 15th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $64.88.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.